Why Moderna (MRNA) Stock Price Was Up 9% on Monday

Shares of Moderna (MRNA) rose 8.7% on Mar 11, after a government website posted details of the initiation of a phase II/III study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. The therapy is being developed in collaboration with Merck (MRK) .The phase II/III study (called INTerpath-007) will evaluate the safety and efficacy of mRNA-4157, combined with Merck’s blockbuster immuno-oncology drug K ...